BeyondSpring BYSI
NASDAQ BYSI
$0.77 +0.16 (+25.70%)
At close: Sep 10, 2026 · 4:00 PM EDT

BeyondSpring (BYSI) Total Non-Current Liabilities (2019 - 2026)

BeyondSpring's (BYSI) quarterly Total Non-Current Liabilities came in at $36.4 million in Q2 2026, down 1.14% year-over-year from $36.9 million in Q2 2025, and little changed quarter-over-quarter from $36.4 million in Q1 2026.

Analysis

BeyondSpring (BYSI) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends

BeyondSpring has disclosed Total Non-Current Liabilities across 8 years of filings, most recently posting $36.4 million for Q2 2026.

  • In Q2 2026, Total Non-Current Liabilities fell 1.14% year-over-year to $36.4 million; the TTM figure through Jun 2026 stood at $36.4 million (down 1.14% YoY), while the FY2025 annual figure was $36.3 million, down 3.31% from the prior year.
  • Total Non-Current Liabilities came in at $36.4 million for Q2 2026 at BeyondSpring, roughly flat from $36.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $41.9 million in Q4 2022 to a low of $36.3 million in Q4 2025.
  • Average Total Non-Current Liabilities over 5 years is $38.3 million, with a median of $37.3 million recorded in 2024.
  • Year-over-year, Total Non-Current Liabilities surged 400.99% in 2022 and declined 6.75% in 2024.
  • Over 5 years, Total Non-Current Liabilities stood at $41.9 million in 2022, then fell by 3.74% to $40.3 million in 2023, then decreased by 6.75% to $37.6 million in 2024, then slipped by 3.31% to $36.3 million in 2025, then increased by 0.25% to $36.4 million in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $36.4 million in Q2 2026, $36.4 million in Q1 2026, and $36.3 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Johnson & Johnson 641.14 Bn 620.38 Bn 17.26 Bn 105.99 Bn
2 AbbVie 451.04 Bn 444.47 Bn 12.70 Bn 106.45 Bn
3 Merck 357.43 Bn 350.29 Bn 12.21 Bn 16.16 Bn
4 Novartis Ag 266.73 Bn 259.04 Bn 11.24 Bn 48.34 Bn
5 Pfizer 157.52 Bn 145.82 Bn 10.94 Bn 100.86 Bn
6 Sanofi 52.14 Bn 44.76 Bn 10.79 Bn 32.04 Bn
7 Revolution Medicines 42.88 Bn 42.88 Bn - 1.53 Bn
8 Incyte 24.70 Bn 20.16 Bn 1.57 Bn 1.40 Bn
9 United Therapeutics 21.47 Bn 18.80 Bn 683.80 Mn 607.80 Mn
10 BeyondSpring 31.51 Mn 31.51 Mn - 36.44 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 36.44 Mn
Mar 31, 2026 36.39 Mn
Dec 31, 2025 36.35 Mn
Sep 30, 2025 36.40 Mn
Jun 30, 2025 36.86 Mn
Mar 31, 2025 37.11 Mn
Dec 31, 2024 37.59 Mn
Jun 30, 2024 38.99 Mn
Dec 31, 2023 40.31 Mn
Jun 30, 2023 40.74 Mn
Dec 31, 2022 41.88 Mn
Jun 30, 2022 40.92 Mn
Dec 31, 2021 40.12 Mn
Sep 30, 2021 40.65 Mn
Jun 30, 2021 8.17 Mn
Mar 31, 2021 8.90 Mn
Dec 31, 2020 11.45 Mn
Sep 30, 2020 3.65 Mn
Jun 30, 2020 3.80 Mn
Mar 31, 2020 3.31 Mn